Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:56:43.145Z.
Consensus retrieved: 2026-10-06T11:06:28.678Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:56:43.145Z.
Quote observation: 2026-10-06T14:55:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d443e069440aa0ac5a32f25afa0d38c48efe58a411ec60778b8439bb1c5cf92a
Forward PE Ratio (N/A) = Dated Quote Price ($2.48) / Consensus Forward EPS ($-0.95)
FORWARD PE RATIO
N/A
Eledon Pharmaceuticals, Inc.
Market Cap
$191.43M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | $191.43M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $190.35M | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.08M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $202.37M | N/A |
| Journey Medical Corporation (DERM)vs › | $178.89M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $173.70M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $173.59M | N/A |
| MediWound Ltd. (MDWD)vs › | $172.45M | N/A |
| Alector, Inc. (ALEC)vs › | $210.39M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.48, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.95 | $-0.95 – $-0.95 | 3 | n/m |
| 2027-12-31 | $-0.83 | $-0.83 – $-0.83 | 2 | n/m |
| 2028-12-31 | $-0.84 | $-1.08 – $-0.66 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
